Probiotics in IgA Nephropathy

Uppsala University Hospital

Status

Unknown

Conditions

IgA Nephropathy

Treatments

Dietary Supplement: ProTectis

Dietary Supplement: Gastrus

Study type

Interventional

Funder types

Other

Identifiers

NCT01781312

SMR-2712 (Other Identifier)

Details and patient eligibility

About

Recent studies have shown an increased gastrointestinal reactivity and increased intestinal permeability in IgA nephropathy (IgAN). Probiotic supplementation is known to impact the gastrointestinal immune system possibly by improvement of both the immunologic and the non-immunologic intestinal barrier. Probiotic supplementation should thus theoretically have an effect on IgAN. In this study the investigators will study the efficacy and safety of Lactobacillus reuteri.

Enrollment

20 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Above 18 years
Primary IgAN, verified by biopsy
Albuminuria > 0.75 g/24 h (verified by at least four sample results within a two years period prior to inclusion)
Serum creatinine less than 200 umol/L (verified by at least four sample results within a two years period prior to inclusion)
Having signed informed consent form

Exclusion criteria

Participation in another clinical intervention trial
Patients with celiac disease
Patients with secondary IgAN
Creatinine clearance below 30 ml/min (mean of 3 measurements)
Introduction of an ACE inhibitor or angiotensin II receptor blocker during the last three months prior to inclusion
Patients treated with immunosuppressive or systemic corticosteroid drugs within the last twelve months
Patients using probiotic products within the last three months (includes probiotic milk products)
Known allergy or intolerance to any of the ingredients in the probiotic product